Withdrawals due to adverse events · of active and inactive people with ulcerative colitis
1 finding from 1 review
Change in symptoms (ranging from 1 week to 3 months) · people with varicose veins without venous ulceration
1 finding from 1 review
Compliance · people with varicose veins without venous ulceration
1 finding from 1 review
Comfort, tolerance and acceptability of wearing stockings (1 week and up to 6 weeks' postpartumc) · people with varicose veins without venous ulceration
1 finding from 1 review
Quality of life · people with varicose veins without venous ulceration
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Measures of physiological function · people with varicose veins without venous ulceration
1 finding from 1 review
Complications (1 week, 4 weeks and up to 6 weeks' postpartumc) · people with varicose veins without venous ulceration
1 finding from 1 review
Compliance · people with varicose veins without venous ulceration
1 finding from 1 review
Comfort, tolerance and acceptability of wearing stockings (1 week and up to 6 weeks' postpartumc) · people with varicose veins without venous ulceration
1 finding from 1 review
Quality of life (3 months) · people with varicose veins without venous ulceration
1 finding from 1 review
Change in symptoms (ranging from 1 week to 3 months) · people with varicose veins without venous ulceration
1 finding from 1 review
Measures of physiological function · people with varicose veins without venous ulceration
1 finding from 1 review
Complications (ranging from 15 minutes to 6 months) · people with varicose veins without venous ulceration
1 finding from 1 review
Failure to induce global or clinical remission · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA leads to lower failure to induce complete global or clinical remission compared with placebo (high certainty).
1 finding from 1 review
Failure to induce endoscopic remission · Patients with active mild to moderate ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to adhere to medication regimen · Patients with active mild to moderate ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA probably leads to lower adverse events compared with SASP (moderate certainty).
1 finding from 1 review
Serious adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in serious adverse events compared with SASP (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA probably leads to lower withdrawal due to adverse events compared with SASP (moderate certainty).
1 finding from 1 review
Failure to induce global or clinical remission · Patients with active mild to moderate ulcerative colitis
Once daily dosing showed no clear difference in failure to induce global or clinical remission compared with conventional dosing (high certainty).
1 finding from 1 review